

Contents of volume 78

Special Issue

Treatment of highly pathogenic RNA viral infections

Guest Editors

Mike Bray

*Integrated Research Facility, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, MD 20892, USA*

Johan Neyts

Rega Institute for Medical Research, Catholic University Leuven, Leuven, Belgium

CONTENTS

Introduction

M. Bray

Highly pathogenic RNA viral infections: Challenges for antiviral research 1

P. Leyssen, E. De Clercq, J. Neyts

Molecular strategies to inhibit the replication of RNA viruses 9

K.B. Spurgers, C.M. Sharkey, K.L. Warfield, S. Bavari

Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses 26

Networks and resources for the development of new therapies

B. Coutard, A.E. Gorbalenya, E.J. Snijder, A.M. Leontovich, A. Poupon, X. De Lamballerie, R. Charrel, E.A. Gould, S. Gunther, H. Norder, B. Klempa, H. Bourhy, J. Rohayem, E. L'hermite, P. Nordlund, D.I. Stuart, R.J. Owens, J.M. Grimes, P.A. Tucker, M. Bolognesi, A. Mattevi, M. Coll, T.A. Jones, J. Åqvist, T. Unge, R. Hilgenfeld, G. Bricogne, J. Neyts, P. La Colla, G. Puerstinger, J.P. Gonzalez, E. Leroy, C. Cambillau, J.L. Romette, B. Canard

The VIZIER project: Preparedness against pathogenic RNA viruses 37

B. Canard, J.S. Joseph, P. Kuhn

International research networks in viral structural proteomics: Again, lessons from SARS 47

H. Greenstone, B. Spinelli, C. Tseng, S. Peacock, K. Taylor, C. Laughlin

NIAID resources for developing new therapies for severe viral infections 51

R. Roberts, B. Styrt, S. McCune

FDA perspective on antivirals against biothreats: Communicate early and often 60

E.S. Higgs, F.G. Hayden, T. Chotpitayasunondh, J. Whitworth, J. Farrar

The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor 64

Animal models*M.R. Holbrook, B.B. Gowen*

Animal models of highly pathogenic RNA viral infections: Encephalitis viruses 69

B.B. Gowen, M.R. Holbrook

Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses 79

Treatment of highly pathogenic RNA viral infections*J. Beigel, M. Bray*

Current and future antiviral therapy of severe seasonal and avian influenza 91

S.H. Khan, A. Goba, M. Chu, C. Roth, T. Healing, A. Marx, J. Fair, M.C. Guttieri, P. Ferro, T. Imes, C. Monagin, R.F. Garry, D.G. Bausch, for the Mano River Union Lassa Fever Network

New opportunities for field research on the pathogenesis and treatment of Lassa fever 103

T.P. Monath

Treatment of yellow fever 116

O. Ergonul

Treatment of Crimean-Congo hemorrhagic fever 125

D.A. Enria, A.M. Briggiler, Z. Sánchez

Treatment of Argentine hemorrhagic fever 132

E.A. Gould, T. Solomon, J.S. Mackenzie

Does antiviral therapy have a role in the control of Japanese encephalitis? 140

D.G. Bausch, A.G. Sprecher, B. Jeffs, P. Boumandouki

Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions 150

C.B. Jonsson, J. Hooper, G. Mertz

Treatment of hantavirus pulmonary syndrome 162

N. Goris, F. Vandenbussche, K. De Clercq

Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock 170

Review*K.E. Luker, G.D. Luker*

Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitation 179

Regular Papers*X. Xu, H. Guo, C. Xiao, Y. Zha, Z. Shi, X. Xia, C. Tu**In vitro* inhibition of classical swine fever virus replication by siRNAs targeting *N^{pro}* and *NS5B* genes 188*M. Nakazawa, S.-e. Kadowaki, I. Watanabe, Y. Kadowaki, M. Takei, H. Fukuda*

PA subunit of RNA polymerase as a promising target for anti-influenza virus agents 194

S. Tengvall, D. O'Hagan, A.M. Harandi

Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: Relative importance of myeloid differentiation factor 88 202

L. Pohjala, V. Barai, A. Azhayev, S. Lapinjoki, T. Ahola

A luciferase-based screening method for inhibitors of alphavirus replication applied to nucleoside analogues 215

B.E. Gilbert, M.T. McLeay

MegaRibavirin aerosol for the treatment of influenza A virus infections in mice 223

J.G. Julander, R. Skirpstunas, V. Siddharthan, K. Shafer, J.D. Hoopes, D.F. Smee, J.D. Morrey

C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection 230

<i>J. Xu, J. Wang, F. Deng, Z. Hu, H. Wang</i> Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro	242
<i>A. McGregor, K.Y. Choi, X. Cui, M.A. McVoy, M.R. Schleiss</i> Expression of the human cytomegalovirus <i>UL97</i> gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir	250
<i>S. Proto, J.A. Taylor, S. Chokshi, N. Navaratnam, N.V. Naoumov</i> APOBEC and iNOS are not the main intracellular effectors of IFN- γ -mediated inactivation of Hepatitis B virus replication	260
<i>I.T.M. Hussein, R.V. Menashy, H.J. Field</i> Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase	268
Short Communications	
<i>V. Bartoňová, V. Král, I. Siegllová, J. Brynda, M. Fábry, M. Hořejší, M. Kožíšek, K.G. Šašková, J. Konvalinka, J. Sedláček, P. Řezáčová</i> Potent inhibition of drug-resistant HIV protease variants by monoclonal antibodies	275
<i>B. Thys, A.M. De Palma, J. Neyts, K. Andries, R. Vrijssen, B. Rombaut</i> R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond	278
Contents of Volume	282